GSK 5-in1 meningitis drug gets US approval

(Sharecast News) - GSK said the US Food and Drug Administration has approved its Penmenvy drug to treat meningitis for use in individuals aged10 - 25 years. The vaccine targets five major serogroups of Neisseria meningitidis (A, B, C, W, and Y) which commonly cause invasive meningococcal disease (IMD).

Penmenvy combines the antigenic components of GSK's two meningococcal vaccines, Bexsero and Menveo. The regulatory application was supported by positive results from two phase III trials, which evaluated its safety, tolerability, and immune response in more than 4,800 participants, GSK said on Monday.

By Frank Prenesti for Sharecast.com